Live
- Kharge signals renewed Cong push for caste census
- Friends with everyone, but no alternative till Modi is PM: Chirag
- Police nab 121 illegal Bangladeshi immigrants
- Light rain, thunderstorms to give relief from heatwave: IMD
- After India’s objections, IMF justifies bailout package to Pak
- Telangana Polycet 2025 Results Announced
- Davanagere doctor loses Rs 2.4 cr to investment fraud
- Trump Warns Apple and Samsung of 25% Tariff on Foreign made iPhones
- Vaibhavam review: A fresh and soulful entertainer
- Skin cancer surges worldwide in older men in last 30 years: Study
Zydus gets USFDA nod to market generic medication
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
New Delhi: Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to market a generic product to treat a rare blood condition.
The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Methylene Blue injection in strengths of 10mg/2ml and 50mg/5ml, the drug firm said in a statement. Zydus' product is the generic version of ProvayBlue injection.
The majority of current market usage is still on the ampoule presentation whereas Zydus is offering a generic version of Methylene Blue injection in vial presentation, the company stated. From a hospital perspective, a vial presentation is an affordable option with significant benefits and advantages, it added.
Methylene Blue injection is an oxidation-reduction agent indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. As per IQVIA MAT data, Methylene Blue injection (10mg/2ml and 50mg/5ml) had an annual sale of around USD 73.4 million in the US.
